Clinical Trial Update: Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on alpelisib plus capecitabine in PIK3CA-mutant metastatic colorectal cancer (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Capecitabine (capecitabine)

Snippet

Sponsor: Korean Cancer Study Group | Conditions: Metastatic Colorectal Cancer, PIK3CA Gene Mutation | Phase 1, Phase 2 | Status: UNKNOWN